Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,shortLongTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,postMarketChangePercent,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,postMarketTime,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,GSK,-24995000000.0,2515749888,1103000000,,1518000000,6145000000,1073000000,2318000000,4980000000,1609000000,1609000000,-50000000,-200000000,,,,258000000,7418000000,5809000000,2438000000,-91000000,,1260000000,1073000000,29418000000.0,3296000000.0,57069000000.0,14865000000.0,3400000000.0,78079000000.0,1346000000.0,308000000.0,6700000000.0,13747000000.0,10442000000.0,3523000000.0,5301000000.0,4757000000.0,20275000000.0,4312000000.0,3523000000.0,10633000000.0,18524000000.0,3761000000.0,60000000.0,7183000000.0,23047000000.0,6216000000.0,13703000000.0,,-41000000.0,0.0,-48000000.0,-54000000.0,-1376000000.0,-1376000000.0,15000000.0,-1128000000.0,-35000000.0,331000000.0,361000000.0,8000000.0,-946000000.0,-391000000.0,273000000.0,-201000000.0,,,-1751000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,GlaxoSmithKline PLC,False,False,NYQ,-0.024330178,41.11,1630526402,0.36999893,41.02,41.21,40.875,2891765,PREPRE,0,2,41.1,-0.010002136,0.9081957,40.875 - 41.21,40.74,0.0,0.0,30,12,finmb_275442,GlaxoSmithKline plc,1630540749,NYSE,GBP,4051003,2867728,7.8500023,0.23601933,33.26 - 42.68,-1.5699997,-0.03678537,33.26,42.68,1633564800,1485964740,1486400400,0.8,14.136864,0.01963672,2.908,3.07,2.86,14.374126,5.942,40.577145,0.532856,0.013131924,38.37384,2.7361603,0.07130275,103422476288,13.39088,6.918546,15,America/New_York,EDT,-14400000,0.4,,,42.68,33.26,40.58,38.37,4.05M,2.87M,2.52B,,2.45B,0.01%,12.64%,18.63M,4.81,,0.74%,23.6M,2.17,5.41%,0.80,1.96%,5.22,76.60%,"Oct 06, 2021","May 19, 2021",2:1,"Nov 11, 1991","Dec 30, 2020","Mar 30, 2021",16.21%,23.63%,5.90%,29.04%,32.43B,13.02,-18.40%,23.21B,9.72B,5.26B,2.91,-31.40%,4.82B,1.93,26.22B,124.79,0.91,5.94,7.81B,8.9B,Value,TW8 9GS,Healthcare,94066,8,1,"GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",Brentford,44 20 8047 5000,1,1609372800,1625097600,3,United Kingdom,http://www.gsk.com,86400,5,980 Great West Road,Drug Manufacturers—General
t-1,GSK,-25834000000.0,2515749888,1322000000,,821000000,6221000000,677000000,2692000000,5777000000,1991000000,1991000000,-228000000,-210000000,,,,-18000000,8739000000,6748000000,2962000000,-1170000000,,839000000,677000000,29824000000.0,3281000000.0,59623000000.0,14587000000.0,5338000000.0,80431000000.0,1346000000.0,195000000.0,7294000000.0,14050000000.0,10597000000.0,2666000000.0,5261000000.0,6292000000.0,22148000000.0,4287000000.0,2666000000.0,11006000000.0,20247000000.0,3496000000.0,480000000.0,6862000000.0,22538000000.0,5996000000.0,4357000000.0,2449000000.0,117000000.0,225000000.0,-52000000.0,-577000000.0,-2175000000.0,-262000000.0,1000000.0,1606000000.0,-22000000.0,3855000000.0,2440000000.0,23000000.0,-946000000.0,-653000000.0,639000000.0,-514000000.0,119000000.0,-224000000.0,-1901000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,GlaxoSmithKline PLC,False,False,NYQ,-0.024330178,41.11,1630526402,0.36999893,41.02,41.21,40.875,2891765,PREPRE,0,2,41.1,-0.010002136,0.9081957,40.875 - 41.21,40.74,0.0,0.0,30,12,finmb_275442,GlaxoSmithKline plc,1630540749,NYSE,GBP,4051003,2867728,7.8500023,0.23601933,33.26 - 42.68,-1.5699997,-0.03678537,33.26,42.68,1633564800,1485964740,1486400400,0.8,14.136864,0.01963672,2.908,3.07,2.86,14.374126,5.942,40.577145,0.532856,0.013131924,38.37384,2.7361603,0.07130275,103422476288,13.39088,6.918546,15,America/New_York,EDT,-14400000,0.4,,,42.68,33.26,40.58,38.37,4.05M,2.87M,2.52B,,2.45B,0.01%,12.64%,18.63M,4.81,,0.74%,23.6M,2.17,5.41%,0.80,1.96%,5.22,76.60%,"Oct 06, 2021","May 19, 2021",2:1,"Nov 11, 1991","Dec 30, 2020","Mar 30, 2021",16.21%,23.63%,5.90%,29.04%,32.43B,13.02,-18.40%,23.21B,9.72B,5.26B,2.91,-31.40%,4.82B,1.93,26.22B,124.79,0.91,5.94,7.81B,8.9B,Value,TW8 9GS,Healthcare,94066,8,1,"GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",Brentford,44 20 8047 5000,1,1609372800,1625097600,3,United Kingdom,http://www.gsk.com,86400,5,980 Great West Road,Drug Manufacturers—General
t-2,GSK,-27266000000.0,2515749888,1066000000,,1671000000,6339000000,1244000000,2489000000,5928000000,2458000000,2458000000,-85000000,-194000000,,,,241000000,8646000000,6188000000,2718000000,-787000000,,1430000000,1244000000,30664000000.0,3280000000.0,60302000000.0,14286000000.0,3092000000.0,80927000000.0,1346000000.0,654000000.0,7055000000.0,14789000000.0,10888000000.0,2605000000.0,5317000000.0,4283000000.0,22179000000.0,4381000000.0,2605000000.0,11205000000.0,19881000000.0,2972000000.0,83000000.0,8421000000.0,23334000000.0,6440000000.0,14173000000.0,2700000000.0,74000000.0,0.0,-560000000.0,-2882000000.0,-4276000000.0,-672000000.0,2000000.0,-4020000000.0,-45000000.0,861000000.0,641000000.0,7000000.0,-946000000.0,-450000000.0,-352000000.0,-292000000.0,119000000.0,-224000000.0,-2298000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,GlaxoSmithKline PLC,False,False,NYQ,-0.024330178,41.11,1630526402,0.36999893,41.02,41.21,40.875,2891765,PREPRE,0,2,41.1,-0.010002136,0.9081957,40.875 - 41.21,40.74,0.0,0.0,30,12,finmb_275442,GlaxoSmithKline plc,1630540749,NYSE,GBP,4051003,2867728,7.8500023,0.23601933,33.26 - 42.68,-1.5699997,-0.03678537,33.26,42.68,1633564800,1485964740,1486400400,0.8,14.136864,0.01963672,2.908,3.07,2.86,14.374126,5.942,40.577145,0.532856,0.013131924,38.37384,2.7361603,0.07130275,103422476288,13.39088,6.918546,15,America/New_York,EDT,-14400000,0.4,,,42.68,33.26,40.58,38.37,4.05M,2.87M,2.52B,,2.45B,0.01%,12.64%,18.63M,4.81,,0.74%,23.6M,2.17,5.41%,0.80,1.96%,5.22,76.60%,"Oct 06, 2021","May 19, 2021",2:1,"Nov 11, 1991","Dec 30, 2020","Mar 30, 2021",16.21%,23.63%,5.90%,29.04%,32.43B,13.02,-18.40%,23.21B,9.72B,5.26B,2.91,-31.40%,4.82B,1.93,26.22B,124.79,0.91,5.94,7.81B,8.9B,Value,TW8 9GS,Healthcare,94066,8,1,"GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",Brentford,44 20 8047 5000,1,1609372800,1625097600,3,United Kingdom,http://www.gsk.com,86400,5,980 Great West Road,Drug Manufacturers—General
t-3,GSK,-28668000000.0,2515749888,1187000000,,2641000000,6544000000,2263000000,2544000000,5195000000,1539000000,1539000000,-75000000,-228000000,,,,201000000,7624000000,6085000000,2429000000,1102000000,,2440000000,2263000000,31263000000.0,3278000000.0,64503000000.0,13593000000.0,3579000000.0,84640000000.0,1346000000.0,833000000.0,6622000000.0,14853000000.0,10998000000.0,2347000000.0,5406000000.0,8166000000.0,23924000000.0,4455000000.0,2347000000.0,11431000000.0,22978000000.0,2564000000.0,87000000.0,7496000000.0,25726000000.0,6396000000.0,14381000000.0,4700000000.0,2644000000.0,0.0,2831000000.0,-606000000.0,-2629000000.0,1571000000.0,3000000.0,2948000000.0,-14000000.0,2760000000.0,-1165000000.0,8000000.0,-1144000000.0,-882000000.0,91000000.0,-223000000.0,119000000.0,-224000000.0,-946000000.0,en-US,US,EQUITY,True,Delayed Quote,USD,us_market,GlaxoSmithKline PLC,False,False,NYQ,-0.024330178,41.11,1630526402,0.36999893,41.02,41.21,40.875,2891765,PREPRE,0,2,41.1,-0.010002136,0.9081957,40.875 - 41.21,40.74,0.0,0.0,30,12,finmb_275442,GlaxoSmithKline plc,1630540749,NYSE,GBP,4051003,2867728,7.8500023,0.23601933,33.26 - 42.68,-1.5699997,-0.03678537,33.26,42.68,1633564800,1485964740,1486400400,0.8,14.136864,0.01963672,2.908,3.07,2.86,14.374126,5.942,40.577145,0.532856,0.013131924,38.37384,2.7361603,0.07130275,103422476288,13.39088,6.918546,15,America/New_York,EDT,-14400000,0.4,,,42.68,33.26,40.58,38.37,4.05M,2.87M,2.52B,,2.45B,0.01%,12.64%,18.63M,4.81,,0.74%,23.6M,2.17,5.41%,0.80,1.96%,5.22,76.60%,"Oct 06, 2021","May 19, 2021",2:1,"Nov 11, 1991","Dec 30, 2020","Mar 30, 2021",16.21%,23.63%,5.90%,29.04%,32.43B,13.02,-18.40%,23.21B,9.72B,5.26B,2.91,-31.40%,4.82B,1.93,26.22B,124.79,0.91,5.94,7.81B,8.9B,Value,TW8 9GS,Healthcare,94066,8,1,"GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",Brentford,44 20 8047 5000,1,1609372800,1625097600,3,United Kingdom,http://www.gsk.com,86400,5,980 Great West Road,Drug Manufacturers—General
